Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Castello, Michael A ^a   Jeppson, John David ^a   Soriano, Salvador ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid beta; Amyloid cascade hypothesis; Anti amyloid therapy; Bapineuzumab; Cholesterol metabolism; Dementia; Familial Alzheimer's disease; Late onset Alzheimer's disease; Neurodegeneration; Solanezumab

Indexed keywords

AMYLOID BETA PROTEIN; BAPINEUZUMAB; SOLANEZUMAB; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; COGNITION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; NERVE DEGENERATION; NEUROPATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; STRESS; AMYLOID PLAQUE; CLINICAL TRIAL (TOPIC); PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; HUMANS; PLAQUE, AMYLOID;

EID: 84921692098     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-014-0169-0     Document Type: Article

References (44)

1. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R: Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:311-321.
2. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:322-333.
3. Karran E, Hardy J: Antiamyloid therapy for Alzheimer's disease-Are we on the right road? N Engl J Med 2014, 370:377-378.
4. Jack CR, Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, Mielke MM, Jones DT, Senjem ML, Gunter JL, Gregg BE, Pankratz VS, Petersen RC: Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013, 81:1732-1740.
5. Herrup K: Reimagining Alzheimer's disease-an age-based hypothesis. J Neurosci 2010, 30:16755-16762.
6. Castello MA, Soriano S: Rational heterodoxy: cholesterol reformation of the amyloid doctrine. Ageing Res Rev 2013, 12:282-288.
7. Castello MA, Soriano S: On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis. Ageing Res Rev 2014, 13C:10-12.
8. Drachman DA: The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement J Alzheimers Assoc 2014, 10:372-380.
9. Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM: Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998, 57:1168-1174.
10. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE: Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008, 65:1509-1517.
11. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ: National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement J Alzheimers Assoc 2012, 8:1-13.
12. Holland JP, Liang SH, Rotstein BH, Collier TL, Stephenson NA, Greguric I, Vasdev N: Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque. J Label Compd Radiopharm 2014, 57:323-331.
13. Selkoe DJ: Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008, 192:106-113.
14. Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL: Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 2013, 73:104-119.
15. Salloway S, Sperling R, Keren R, Porsteinsson AP, Van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM, For the ELND005-AD201 Investigators: A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011, 77:1253-1262.
16. Golde TE, Schneider LS, Koo EH: Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 2011, 69:203-213.
17. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC: Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003, 62:1087-1095.
18. Braak H, Thal DR, Ghebremedhin E, Del Tredici K: Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100years. J Neuropathol Exp Neurol 2011, 70:960-969.
19. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc Natl Acad Sci 1985, 82:4245-4249.
20. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
21. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L: A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat Genet 1992, 1:345-347.
22. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ: Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 2011, 108:5819-5824.
23. Li C, Ebrahimi A, Schluesener H: Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease. Ageing Res Rev 2013, 12:116-140.
24. Bloom GS: Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 2014, 71:505-508.
25. Bignante EA, Heredia F, Morfini G, Lorenzo A: Amyloid β precursor protein as a molecular target for amyloid β-induced neuronal degeneration in Alzheimer's disease. Neurobiol Aging 2013, 34:2525-2537.
26. Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
27. Blennow K, De Leon MJ, Zetterberg H: Alzheimer's disease. Lancet 2006, 368:387-403.
28. Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JSK, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, et al: Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011, 43:436-441.
29. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J-C, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, et al: Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011, 43:429-435.
30. Bali J, Gheinani AH, Zurbriggen S, Rajendran L: Role of genes linked to sporadic Alzheimer's disease risk in the production of β-amyloid peptides. Proc Natl Acad Sci U S A 2012, 109:15307-15311.
31. Obrenovich ME, Joseph JA, Atwood CS, Perry G, Smith MA: Amyloid-β: a (life) preserver for the brain. Neurobiol Aging 2002, 23:1097-1099.
32. Castellani RJ, Smith MA: Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is "too big to fail.". J Pathol 2011, 224:147-152.
33. Lee H, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA: Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther 2007, 321:823-829.
34. Benilova I, Karran E, De Strooper B: The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012, 15:349-357.
35. Marchesi VT: Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 2011, 25:5-13.
36. Stranahan AM, Mattson MP: Recruiting adaptive cellular stress responses for successful brain ageing. Nat Rev Neurosci 2012, 13:209-216.
37. Valdez CM, Phelix CF, Smith MA, Perry G, Santamaria F: Modeling cholesterol metabolism by gene expression profiling in the hippocampus. Mol Biosyst 2011, 7:1891-1901.
38. Freiherr J, Hallschmid M, Frey WH 2nd, Brünner YF, Chapman CD, Hölscher C, Craft S, De Felice FG, Benedict C: Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013, 27:505-514.
39. Gervain J, Vines BW, Chen LM, Seo RJ, Hensch TK, Werker JF, Young AH: Valproate reopens critical-period learning of absolute pitch. Front Syst Neurosci 2013, 7:102.
40. Puzzo D, Privitera L, Leznik E, Fà M, Staniszewski A, Palmeri A, Arancio O: Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008, 28:14537-14545.
41. Garcia-Osta A, Alberini CM: Amyloid beta mediates memory formation. Learn Mem 2009, 16:267-272.
42. Morley JE, Farr SA: The role of amyloid-beta in the regulation of memory. Biochem Pharmacol 2014, 88:479-485.
43. Wang W, Mutka A-L, Zmrzljak UP, Rozman D, Tanila H, Gylling H, Remes AM, Huttunen HJ, Ikonen E: Amyloid precursor protein aα- and β-cleaved ectodomains exert opposing control of cholesterol homeostasis via SREBP2. FASEB J Off Publ Fed Am Soc Exp Biol 2014, 28:849-860.
44. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M: Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012, 11:241-249.